The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia
Open accessAbstract
BACKGROUND AND AIMS: Substantial residual cardiovascular risks remain despite intensive statin treatment. Residual risks with high triglyceride and low high-density lipoprotein cholesterol are not the primary targets of statins. K-877 (pemafibrate) demonstrated robust efficacy on triglycerides and high-density lipoprotein cholesterol and a good safety profile as a monotherapy. The aim of these studies was to evaluate the efficacy and safety of K-877 add-on therapy to treat residual hypertriglyceridaemia during statin treatment. METHODS: The objectives were investigated in two, multicentre, randomised, double-blind, placebo-controlled, parallel group comparison clinical trials: (A) K-877 0.1, 0.2, and 0.4 mg/day in combination with pitavastatin for 12 weeks in 188 patients, (B) K-877 0.2 (fixed dose) and 0.2 (0.4) (conditional up-titration) mg/day in combination with any statin for 24 weeks in 423 patients. RESULTS: In both studies, we found a robust reduction in fasting triglyceride levels by approximately 50% in all combination therapy groups, which was significant compared to the statin-monotherapy (placebo) groups (p < 0.001). High-performance liquid chromatography analysis for lipoprotein subfractions revealed that atherogenic lipoprotein profiles were ameliorated by K-877 add-on therapy, i.e. small low-density lipoproteins decreased whereas larger ones increased, and larger high-density lipoproteins decreased whereas smaller ones increased. The incidence rates of adverse events and adverse drug reactions in K-877 combination therapy groups were comparable to those in statin-monotherapy groups without any noteworthy event in both studies. CONCLUSIONS: These results strongly support the favourable benefit-to-risk ratio of K-877 add-on therapy in combination with statin treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Data from Arai 2017, Araki 2018, Araki 2019, Dai 2025, Das 2022, Ginsberg 2022, and Matsuba 2018 showed an RR of 1.02 (95% CI: 0.98, 1.07, p = 0.30), suggesting no significant difference in total adverse events between pemafibrate and placebo (I2 = 0%) (high certainty).”
From Pemafibrate for hypertriglyceridemia: a meta-analysis of randomized controlled trials evaluating efficacy and safety outcomes (2026) · cites this paper as Arai 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–125 of 125
Yamashita, S., Araki, E., Arai, H., Yokote, K., Tanigawa, R., Saito, A., Suganami, H., Minamikawa, S., & Ishibashi, S. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65707 · Cited by 3
Self-citationKudinov, V. A., Zakharova, T. S., Torkhovskaya, T. I., Ipatova, O. M., & Archakov, A. I. (2018) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750818020075 · Cited by 3
Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00004-2 · Cited by 1
Watanabe, M., Nakanishi, M., Shingaki, W., Gunji, R., Makinose, Y., Kanno, T., & Ishibashi, S. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03294-5 · Cited by 1
Self-citationHypertriglyzeridämie und HDL-Mangel
von Eckardstein, A. (2017) · Praxis · doi:10.1024/1661-8157/a002760 · Cited by 1
Fujioka, Y. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed088 · Cited by 1
Kobuchi, S., Shigemura, A., Ιtο, Y., & Sakaeda, T. (2020) · Bioanalysis · doi:10.4155/bio-2020-0081 · Cited by 1
Akasaki, Y. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed266 · Cited by 1
Ueda, H., Mineo, R., Sugiyama, T., Koseki, M., Itoh, Y., Iwamoto, R., Tamba, S., Yamamoto, K., Yamada, Y., Hiraoka, H., et al. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3946-24 · Cited by 1
The Clinical Implication of Pemafibrate, a Novel Selective PPARα Modulator
Fujioka, Y. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed275 · Cited by 1
Okamoto, A., Yokokawa, H., Nagamine, T., Goto, K., Fukuda, H., Hisaoka, T., & Naito, T. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01872-w · Cited by 1
Kudinov, V. A., Zakharova, T. S., Torkhovskaya, T. I., Ipatova, O. M., & Archakov, A. I. (2018) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20186401066 · Cited by 1
Masood, M. A., Qureshi, M. A. M., Zahoor, H. S., Arshad, A., & Nazakat, A. (2026) · Systematic Reviews · doi:10.1186/s13643-026-03186-x
“Data from Arai 2017, Araki 2018, Araki 2019, Dai 2025, Das 2022, Ginsberg 2022, and Matsuba 2018 showed an RR of 1.02 (95% CI: 0.98, 1.07, p = 0.30), suggesting no significant difference in total adverse events between pemafibrate and placebo ( I 2 = 0”
InfluentialHypertriglyzeridämie und HDL-Mangel
von Eckardstein, A. (2017) · CardioVasc · doi:10.1007/s15027-017-1275-x
Lipid Management for Prevention of Atherosclerotic Cardiovascular Diseases
Yamashita, S. (2018) · Health Evaluation and Promotion · doi:10.7143/jhep.45.755
Self-citationHigh-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?
Nelson, A. J., Mirzaee, S., & Nicholls, S. J. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00363-3
de Toro, C. L., & del Valle, I. D. (2013)
Farnier, M. (2021) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(21)45461-9
Pulipati, V. P., & Brinton, E. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00023-6
Brinton, E. A., & Pulipati, V. P. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_24
Takamiya, Y., Imanaga, C., Ike, A., Kawamura, A., & Urata, H. (2024) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2024.200359
Lu, B., Biao, L. I., Zhou, M., Liu, Y., Liu, H., Huang, W., Song, H., Cai, W., Tan, B., & Dong, X. (2025) · Aquaculture Reports · doi:10.1016/j.aqrep.2025.102747
Kusunoki, M., Hisano, F., Matsuda, S., Kusunoki, A., Tsutsumi, K., & Miyata, T. (2025) · Drug Research · doi:10.1055/a-2560-9750
Ishii, M., Fujisue, K., Kaikita, K., Yamanaga, K., Hanatani, S., Matsuzawa, Y., Miura, M., Kudo, T., Shimomura, H., Takae, M., et al. (2026) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65984
BindingDB Entry 50007904: Synthetic Approaches to the New Drugs Approved During 2017.
BindingDB (2021) · UC San Diego · doi:10.7270/q2sx6hk5
Metadata
- Authors
- Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., & Ishibashi, S.
- Affiliations
- National Center for Geriatrics and Gerontology (JP)
- Rinku General Medical Center (JP)
- Chiba University (JP)
- Kumamoto University (JP)
- Kowa (Japan) (JP)
- Jichi Medical University (JP)
- Corresponding author
- Arai, Hidenori
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 261
- Pages
- 144-152
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W2599479486
- Cited by
- 124
- References
- 46
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 11 · 2023: 16 · 2022: 10 · 2021: 13 · 2020: 13 · 2019: 18 · 2018: 16 · 2017: 13
- FWCI
- 16.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Atherosclerosis (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Kowa Company
- Astellas Pharma
- Japan Society for the Promotion of Science (17H02100)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- pemafibrate, statin combination therapy, dyslipidemia, triglyceride lowering, HDL cholesterol, atherogenic lipoprotein profile, pitavastatin, adjunctive therapy, drug safety
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Benzoxazoles, Butyrates, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Japan, Male, Middle Aged, Quinolines, Time Factors, Triglycerides, Hypertriglyceridemia, Signal Transduction, Biomarkers, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, PPAR alpha, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
